ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium (Q37145440)

18 August 2017

1 reference

title

ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium (English)

1 reference

18 August 2017

Stephen J Fuller

1

1 reference

PubMed ID

18430438

18 August 2017

Kenga Sivarajah

series ordinal

2

1 reference

PubMed ID

18430438

18 August 2017

Peter H Sugden

series ordinal

3

1 reference

18 August 2017

4 March 2008

1 reference

Journal of Molecular and Cellular Cardiology

18 August 2017

1 reference

18 August 2017

44

1 reference

18 August 2017

5

1 reference

18 August 2017

831-854

1 reference

The discovery of receptor tyrosine kinases: targets for cancer therapy

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Expression Cloning of Human EGF Receptor Complementary DNA: Gene Amplification and Three Related Messenger RNA Products in A431 Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Molecular cloning and expression of an additional epidermal growth factor receptor-related gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Structure of the extracellular region of HER3 reveals an interdomain tether

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Epidermal growth factor receptor: mechanisms of activation and signalling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The EGF Receptor Hokey-Cokey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The EGF receptor family as targets for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The ErbB signaling network: receptor heterodimerization in development and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Untangling the ErbB signalling network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The deaf and the dumb: the biology of ErbB-2 and ErbB-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

ErbB receptors: directing key signaling networks throughout life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The ErbB/HER receptor protein-tyrosine kinases and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

EGF-ERBB signalling: towards the systems level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

ErbB receptors: new insights on mechanisms and biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Signaling through ERBB receptors: multiple layers of diversity and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The EGF receptor family: spearheading a merger of signaling and therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

A quantitative protein interaction network for the ErbB receptors using protein microarrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Association with membrane protrusions makes ErbB2 an internalization-resistant receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

ErbB-4: mechanism of action and biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Nuclear localization and possible functions of receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Nuclear signaling by receptor tyrosine kinases: the first robin of spring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Membrane-anchored growth factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Autocrine, paracrine and juxtacrine signaling by EGFR ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulins: functions, forms, and signaling strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Characterization of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

SH2 and PTB domains in tyrosine kinase signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Phosphotyrosine interactome of the ErbB-receptor kinase family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Quantitative proteomic assessment of very early cellular signaling events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Signal transduction by growth factor receptors: signaling in an instant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cell signaling by receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Regulation of cardiac hypertrophy by intracellular signalling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Mitogen-activated protein kinases in heart development and diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The PI3K-PDK1 connection: more than just a road to PKB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Synthesis and function of 3-phosphorylated inositol lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Regulation of Akt/PKB Ser473 phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

7 January 2021

The two TORCs and Akt.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

7 January 2021

The renaissance of GSK3

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

GSK3 takes centre stage more than 20 years after its discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

TOR signaling in growth and metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

FOXO factors: a matter of life and death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Glycogen synthase kinase-3beta -- actively inhibiting hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The multiple function of Grb2 associated binder (Gab) adaptor/scaffolding protein in immune cell signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Negative regulation of ErbB family receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

"To erb-B or not to erb-B..." Neuregulin-1/ErbB signaling in heart development and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

ErbB and HB-EGF signaling in heart development and function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Temporal regulation of expression of immediate early and second phase transcripts by endothelin-1 in cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin receptor ErbB2 localization at T-tubule in cardiac and skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Strain-dependent epithelial defects in mice lacking the EGF receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Generation and characterization of neuregulin-2-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Requirement for neuregulin receptor erbB2 in neural and cardiac development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Severe neuropathies in mice with targeted mutations in the ErbB3 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Signals from both sides: Control of cardiac development by the endocardium and epicardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Multiple essential functions of neuregulin in development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Apoptosis and anthracycline cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cysteine-rich domain isoforms of the neuregulin-1 gene are required for maintenance of peripheral synapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

ErbB2 is essential in the prevention of dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cellular mechanisms of cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Controversies in ventricular remodelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Peptide growth factors signal differentially through protein kinase C to extracellular signal-regulated kinases in neonatal cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

MAP kinase mediates epidermal growth factor- and phorbol ester-induced prostacyclin formation in cardiomyocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Myocyte contractile activity modulates norepinephrine cytotoxicity and survival effects of neuregulin-1β

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Regulation of bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Regulation of protein kinase B and 4E-BP1 by oxidative stress in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Molecular and cellular mechanisms of anthracycline cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Pathophysiology and diagnosis of cancer drug induced cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Apoptosis-modulating interaction of the neuregulin/erbB pathway with anthracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The EGF receptor as central transducer of heterologous signalling systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

ADAMs in cancer cell proliferation and progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Agonist-induced interactions between angiotensin AT1 and epidermal growth factor receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Role of EGF Receptor and Pyk2 in endothelin-1-induced ERK activation in rat cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

PKCdelta signaling: mechanisms of DNA damage response and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

erbB2 is required for G protein-coupled receptor signaling in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

UTP transactivates epidermal growth factor receptors and promotes cardiomyocyte hypertrophy despite inhibiting transcription of the hypertrophic marker gene, atrial natriuretic peptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Galphaq expression activates EGFR and induces Akt mediated cardiomyocyte survival: dissociation from Galphaq mediated hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Ras activation in response to lysophosphatidic acid requires a permissive input from the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Ras activation in response to phorbol ester proceeds independently of the EGFR via an unconventional nucleotide-exchange factor system in COS-7 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Tumor promoters block tyrosine-specific phosphorylation of the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Protein kinase Calpha mediates feedback inhibition of EGF receptor transactivation induced by Gq-coupled receptor agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Using U0126 to dissect the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Induction of heparin-binding epidermal growth factor-like growth factor mRNA by protein kinase C activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Caloric restriction and mitochondrial function in the ageing myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin in Cardiac Hypertrophy in Rats With Aortic Stenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Neuregulin receptors erbB2 and erbB4 in failing human myocardium -- depressed expression and attenuated activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Humanization of an anti-p185HER2 antibody for human cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Herceptin: mechanisms of action and resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Trastuzumab: triumphs and tribulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Clinical cardiac tolerability of trastuzumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

7 January 2021

Targeting HER2 Epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Lapatinib in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Tolerability of gefitinib in patients receiving treatment in everyday clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

Effect of dominant-negative epidermal growth factor receptors on cardiomyocyte hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.02.278

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YJMCC.2008.02.278

1 reference

18 August 2017

1 reference

PubMed ID

18430438